Amylin analysts advise caution amid stock run-up

Amylin Pharmaceuticals analysts are advising investors to proceed with caution given Wednesday’s massive run-up in the stock on a report that Bristol-Meyers had made a bid for the company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.